**Appendix C – Results for patient-reported outcome measures**

|  |  |
| --- | --- |
|  | **Trial visit** |
| **1** | **2** | **3** | **4** |
| **Breathlessness** | IMP | 36(-28.4 to 100.4) | 29.8(-31.5 to 91.0) | 13.6 (-9.5 to 36.8) | 20.3 (-4.5 to 45.1) |
| Control | 17.3(-30.5 to 65.1) | 3.0(-14.6 to 20.6) | 0(-17.6 to 17.6) | 19.3(-27.4 to 66.1) |
| **Chest pain** | IMP | 16.6(-46.6 to 79.8) | 10.5 (-29.4 to 50.4) | 2(-3.3 to 7.3) | 11.8 (-23.4 to 47.0) |
| Control | 5.7 (-3.4 to 14.8) | 0(n/a) | 1(n/a) | 3.7(-7.1 to 14.5) |
| **Sweating** | IMP | 0.6(-1.2 to 2.5) | 14.5 (-30.2 to 59.2) | 10(-19.2 to 39.2) | 1.3(-0.9 to 3.6) |
| Control | 5.8(-4.9 to 16.6) | 0(n/a) | 0(n/a) | 3.0 (-7.2 to 13.2) |
| **Quality of life** | IMP | 80(64.0 to 96.0) | 77.5 (37.9 to 117.1) | 76.3 (35.9 to 116.5) | 83.3(58.7 to 108.0) |
| Control | 80(37.3 to 122.7) | 90(76.1 to 103.9) | 80 (52.3 to 107.7) | 66.7 (25.8 to 107.5) |



Figure C1 - Patient reported symptom scores (mean and 95% confidence intervals) for breathlessness in people randomised to receive an IMP compared with controls at each study visit



Figure C2 - Patient reported symptom scores (mean and 95% confidence intervals) for chest pain for people randomised to receive an IMP compared with controls at each study visit



Figure C3 - Patient reported symptom scores (mean and 95% confidence intervals) for sweats in people randomised to receive an IMP compared with controls at each study visit



Figure C4 - Patient reported symptom scores (mean and 95% confidence intervals) for quality of life in people randomised to receive OK432 or BCG compared with controls at each study visit